Planisware expands its Asia-Pacific footprintwith the opening of an office andtwo new data centers in Australia Paris, France, December 11, 2025 - Planisware, a leading provider of B2B AI-powered SaaS platforms serving the rapidly growing Project Economy, announces the opening of an office and two new data centers in Australia. This dual initiative marks an important step in the group's international development strategy and consolidates its presence in the Asia-Pacific region, where Planisware already has ...

Core Insights - ABN AMRO has completed a significant risk transfer transaction with Blackstone, providing first loss protection on a EUR 2 billion portfolio of large corporate loans [1] - The transaction aims to reduce ABN AMRO's risk-weighted assets by EUR 1.6 billion, while offering Blackstone exposure to a diversified portfolio of large corporate clients [2] - This transaction is part of ABN AMRO's strategy to reallocate up to EUR 8 billion in risk-weighted assets through active portfolio management [3] Company Overview: ABN AMRO - ABN AMRO is one of the largest banks in the Netherlands, focusing on personal banking in the digital age and offering sector expertise [4] - The bank operates a Wealth Management unit that is a leading private bank in the Netherlands, Germany, France, and Belgium, and provides banking and advisory services through its Corporate Banking unit [4] Company Overview: Blackstone - Blackstone is the world's largest alternative asset manager, managing over $1.2 trillion in assets across various global investment strategies [5] - The firm aims to deliver compelling returns for institutional and individual investors by strengthening the companies in which it invests [5]

Core Insights - Nilfisk's US business has not seen the expected improvement in market activity and order intake for November and early December, leading to a revised outlook for organic growth in 2025 [1] - The company now anticipates organic revenue growth to be in the range of 0% to 1%, down from a previous expectation of around 1% [2] - Nilfisk maintains its EBITDA margin forecast before special items at 13% to 14%, which includes profit contributions from associates [2] Financial Outlook - Revised organic revenue growth for 2025: 0% to 1% compared to the previous outlook of around 1% [2] - EBITDA margin before special items remains unchanged at 13% to 14% [2] Operational Challenges - Short-term issues with a supplier have restricted the ability to ship full volumes of two products before year-end [1]

Core Points - Sampo plc has initiated a share buyback program with a maximum limit of EUR 150 million, which commenced on 6 November 2025 [1][2] - On 10 December 2025, Sampo plc acquired a total of 260,223 A shares at an average price of EUR 10.04 per share [1] - Following these transactions, Sampo plc now holds a total of 6,130,758 A shares, representing 0.23% of the total shares outstanding [2] Summary by Category Share Buyback Program - The share buyback program was announced on 5 November 2025 and is in compliance with the Market Abuse Regulation (EU) 596/2014 [1] - The program is based on the authorization granted by Sampo's Annual General Meeting on 23 April 2025 [1] Transaction Details - The daily buyback on 10 December 2025 included shares purchased across multiple markets: AQEU (4,807 shares), CEUX (118,843 shares), TQEX (27,929 shares), and XHEL (108,644 shares) [1] - The aggregated daily volume of shares bought back was 260,223 shares at a consistent average price of EUR 10.04 [1] Ownership Post-Transaction - After the buybacks, Sampo plc's total ownership of A shares stands at 6,130,758, which constitutes 0.23% of the total shares [2]

Core Viewpoint - Immunovant, Inc. has announced an underwritten offering of common stock expected to raise approximately $550 million to support its operations and the potential commercial launch of IMVT-1402 for Graves' Disease [1][2]. Group 1: Offering Details - The company is offering 26.2 million shares at a price of $21.00 per share, with the offering expected to close around December 12, 2025, pending customary closing conditions [3]. - Roivant Sciences Ltd., the controlling stockholder of Immunovant, has agreed to purchase shares in this offering [1]. Group 2: Financial Implications - The proceeds from the offering, combined with existing cash and cash equivalents, are anticipated to be sufficient to fund operating expenses and capital expenditures through the potential commercial launch of IMVT-1402 [2].

Core Insights - Basilea Pharmaceutica Ltd has announced a partnership with Phare Bio Inc. to leverage AI for antibiotic discovery, addressing the urgent need for new antibiotics in the face of antimicrobial resistance [1][2][3] Company Overview - Basilea Pharmaceutica Ltd is a commercial-stage biopharmaceutical company focused on developing innovative drugs for severe bacterial and fungal infections, with two successful hospital brands, Cresemba and Zevtera, already launched [5] - Phare Bio Inc. is a biotech social venture founded in 2020, utilizing AI to develop novel antibiotics and backed by organizations like The Audacious Project and Google.org [4] Partnership Details - The partnership will utilize Phare Bio's Generative AI platform to design antibacterial molecules that meet specific medical and commercial criteria, with Basilea responsible for further development [2] - Phare Bio will receive success-based payments upon achieving predefined milestones, marking a new model for antibiotic innovation that combines technological advances with industrial expertise [2][3] Strategic Importance - The collaboration is seen as a significant step in combating antimicrobial resistance, aligning AI-driven drug discovery with a commitment to developing innovative antibiotics [3] - Both companies emphasize the importance of addressing public health crises through innovative drug development and collaboration [3]

Core Insights - Zealand Pharma aims to redefine weight management and establish leadership in metabolic health through its Metabolic Frontier 2030 strategy, focusing on innovative solutions for obesity and metabolic diseases [2][4][5] Company Strategy - The company plans to target five product launches and maintain a clinical pipeline of over ten programs by 2030, utilizing its peptide expertise and advanced research capabilities to enhance drug discovery [3][7] - Zealand Pharma will leverage strategic partnerships and advanced computational methods to accelerate drug development and expand its molecule-making toolbox [3][6] Research and Development - A new research site in Boston will integrate over 25 years of peptide expertise with AI-driven drug discovery and advanced automation, aiming to enhance the efficiency of drug development [6][7] - The company anticipates multiple clinical readouts in 2026, including Phase 2 data for petrelintide and Phase 3 data for survodutide [7] Leadership and Vision - The CEO, Adam Steensberg, emphasizes the company's commitment to transforming treatment approaches for obesity and metabolic diseases, moving beyond traditional weight loss methods to support overall well-being [4][5] - Zealand Pharma's strategy is designed to address significant healthcare challenges and foster innovation in metabolic health [5]

Core Viewpoint - Ontex has appointed Mr. Laurent Nielly as the new Chief Executive Officer, effective from May 5, 2026, succeeding Mr. Gustavo Calvo Paz, who has led the company through a strategic transformation [1][3]. Group 1: Leadership Transition - Mr. Laurent Nielly has been with Ontex since 2021 as President of the Europe Division, overseeing retailer brands and healthcare business across Europe [2]. - Nielly has over 25 years of experience in various regions and companies, including P&G, McKinsey & Company, PepsiCo, and Coty, with a background in finance, strategy, innovation, and commercial excellence [2]. - The Board of Directors expressed gratitude to Mr. Calvo Paz for his contributions, particularly in implementing strategic changes and optimizing Ontex's operations [3][4]. Group 2: Strategic Direction - Under Mr. Calvo Paz's leadership, Ontex focused on divesting non-core activities and optimizing its operational footprint, aiming to future-proof the organization with a focus on Europe and North America [3]. - The Board believes that Mr. Nielly is well-positioned to build on the accomplishments of his predecessor and accelerate value creation for Ontex [4]. Group 3: Company Overview - Ontex is a leading international developer and producer of baby care, feminine care, and adult care products, primarily serving retailers and healthcare sectors in Europe and North America [6]. - The company employs around 5,100 people and operates in 11 countries, with its products distributed in approximately 100 countries [6].

Core Insights - Atos and N3XT Sports have formed a strategic partnership to enhance digital transformation and growth in Saudi Arabia's sports market [1][2] - The collaboration aims to provide comprehensive digital solutions, including data transformation, smart-venue integration, and customized infrastructure development [2][6] - The partnership will leverage Atos' extensive experience in major sporting events and N3XT Sports' regional expertise to drive innovation and engagement in Saudi Arabia's sports ecosystem [3][4][6] Company Overview - Atos is a global leader in digital transformation with approximately 67,000 employees and annual revenue of around €10 billion, operating in 61 countries [9] - N3XT Sports is a specialized agency focused on strategy development and digital transformation in the sports industry, with a strong presence in Europe and the Middle East [4][8] - Both companies aim to enhance fan, athlete, and stakeholder engagement through advanced technology and operational support [2][6][9]

Core Insights - BioVersys AG has initiated its lead asset BV100 Phase 3 clinical program, focusing on novel antibacterial products for serious infections caused by multi-drug resistant bacteria [2][4] - The company completed a successful IPO on February 7, 2025, raising CHF 76.7 million, marking the largest biotech IPO in Switzerland in seven years [3][8] - Significant clinical advancements were made in 2025, including strong Phase 2 data for BV100, which demonstrated a 50% relative reduction in all-cause mortality in patients with drug-resistant infections [4][8] Financial Developments - The IPO proceeds will fund BioVersys' operations into 2028, including the completion of the BV100 Phase 3 trial [3][8] - BioVersys received a CHF 5 million upfront payment from Shionogi as part of a global research collaboration for the BV500 program, with potential milestones of up to CHF 479 million [10] Clinical Trials and Research - The BV100 Phase 3 trial will include sites in the US, Europe, Latin America, Asia, and China, with first patient dosing expected in the coming months [5][8] - A Phase 2b trial comparing BV100 to best available therapy is planned, with funding from ADVANCE-ID, significantly reducing BioVersys' financial contribution [7][8] - The company is also advancing the alpibectir program in partnership with GSK, with a Phase 2 trial in pulmonary tuberculosis expected to report topline data by Q2 2026 [11][12] Future Milestones - Key upcoming milestones include the first patients dosed in the BV100 Phase 3 study in Q1 2026, interim data read-out for the Phase 2b trial in H2 2026, and top line data for the Phase 3 trial expected in H2 2027 [16]